UA75395C2 - Method for inhibiting adhesion formation - Google Patents
Method for inhibiting adhesion formation Download PDFInfo
- Publication number
- UA75395C2 UA75395C2 UA2003109182A UA2003109182A UA75395C2 UA 75395 C2 UA75395 C2 UA 75395C2 UA 2003109182 A UA2003109182 A UA 2003109182A UA 2003109182 A UA2003109182 A UA 2003109182A UA 75395 C2 UA75395 C2 UA 75395C2
- Authority
- UA
- Ukraine
- Prior art keywords
- alkyl
- halogen
- equals
- cycloalkyl
- pharmaceutically acceptable
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 20
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910002701 Ag-Co Inorganic materials 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- -1 methylenedioxy Chemical group 0.000 claims description 7
- 229910017709 Ni Co Inorganic materials 0.000 claims description 4
- 229910003267 Ni-Co Inorganic materials 0.000 claims description 4
- 229910003262 Ni‐Co Inorganic materials 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 241001446467 Mama Species 0.000 claims 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 claims 1
- 238000004651 near-field scanning optical microscopy Methods 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 abstract description 14
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract description 14
- 239000002464 receptor antagonist Substances 0.000 abstract description 4
- 229940044551 receptor antagonist Drugs 0.000 abstract description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011068 loading method Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010060932 Postoperative adhesion Diseases 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- PGOOBECODWQEAB-UHFFFAOYSA-N (E)-clothianidin Chemical compound [O-][N+](=O)\N=C(/NC)NCC1=CN=C(Cl)S1 PGOOBECODWQEAB-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108091036429 KCNQ1OT1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010061401 Uterine injury Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28269301P | 2001-04-10 | 2001-04-10 | |
| PCT/US2002/011285 WO2002083125A1 (en) | 2001-04-10 | 2002-04-10 | Method of inhibiting adhesion formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75395C2 true UA75395C2 (en) | 2006-04-17 |
Family
ID=23082703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003109182A UA75395C2 (en) | 2001-04-10 | 2002-10-04 | Method for inhibiting adhesion formation |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1385504B1 (pt) |
| JP (1) | JP4394882B2 (pt) |
| KR (1) | KR20030087069A (pt) |
| CN (1) | CN1248692C (pt) |
| AP (1) | AP2003002894A0 (pt) |
| AT (1) | ATE417612T1 (pt) |
| AU (1) | AU2002305164B2 (pt) |
| BG (1) | BG108217A (pt) |
| BR (1) | BR0208789A (pt) |
| CA (1) | CA2443734A1 (pt) |
| CZ (1) | CZ20032767A3 (pt) |
| DE (1) | DE60230404D1 (pt) |
| EA (1) | EA006202B1 (pt) |
| EC (1) | ECSP034799A (pt) |
| ES (1) | ES2319877T3 (pt) |
| HU (1) | HUP0303725A3 (pt) |
| IL (1) | IL158272A0 (pt) |
| MA (1) | MA26159A1 (pt) |
| MX (1) | MXPA03009344A (pt) |
| NO (1) | NO20034513L (pt) |
| NZ (1) | NZ528577A (pt) |
| OA (1) | OA12505A (pt) |
| PL (1) | PL364526A1 (pt) |
| UA (1) | UA75395C2 (pt) |
| WO (1) | WO2002083125A1 (pt) |
| ZA (1) | ZA200307621B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841406A4 (en) * | 2004-12-21 | 2008-06-25 | Smithkline Beecham Corp | METHOD AND FORMULATIONS |
| RU2744540C1 (ru) * | 2020-02-18 | 2021-03-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
2002
- 2002-04-10 WO PCT/US2002/011285 patent/WO2002083125A1/en active IP Right Grant
- 2002-04-10 KR KR10-2003-7013214A patent/KR20030087069A/ko active IP Right Grant
- 2002-04-10 OA OA1200300271A patent/OA12505A/en unknown
- 2002-04-10 JP JP2002580929A patent/JP4394882B2/ja not_active Expired - Fee Related
- 2002-04-10 AU AU2002305164A patent/AU2002305164B2/en not_active Ceased
- 2002-04-10 NZ NZ528577A patent/NZ528577A/en unknown
- 2002-04-10 PL PL02364526A patent/PL364526A1/xx not_active Application Discontinuation
- 2002-04-10 EP EP02733968A patent/EP1385504B1/en not_active Expired - Lifetime
- 2002-04-10 ES ES02733968T patent/ES2319877T3/es not_active Expired - Lifetime
- 2002-04-10 AT AT02733968T patent/ATE417612T1/de not_active IP Right Cessation
- 2002-04-10 BR BR0208789-8A patent/BR0208789A/pt not_active IP Right Cessation
- 2002-04-10 AP APAP/P/2003/002894A patent/AP2003002894A0/en unknown
- 2002-04-10 IL IL15827202A patent/IL158272A0/xx unknown
- 2002-04-10 HU HU0303725A patent/HUP0303725A3/hu unknown
- 2002-04-10 CN CNB028097874A patent/CN1248692C/zh not_active Expired - Fee Related
- 2002-04-10 DE DE60230404T patent/DE60230404D1/de not_active Expired - Lifetime
- 2002-04-10 EA EA200301109A patent/EA006202B1/ru not_active IP Right Cessation
- 2002-04-10 CA CA002443734A patent/CA2443734A1/en not_active Abandoned
- 2002-04-10 MX MXPA03009344A patent/MXPA03009344A/es active IP Right Grant
- 2002-04-10 CZ CZ20032767A patent/CZ20032767A3/cs unknown
- 2002-10-04 UA UA2003109182A patent/UA75395C2/uk unknown
-
2003
- 2003-09-30 ZA ZA200307621A patent/ZA200307621B/en unknown
- 2003-10-01 BG BG108217A patent/BG108217A/bg unknown
- 2003-10-06 MA MA27339A patent/MA26159A1/fr unknown
- 2003-10-08 NO NO20034513A patent/NO20034513L/no not_active Application Discontinuation
- 2003-10-09 EC EC2003004799A patent/ECSP034799A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4394882B2 (ja) | 2010-01-06 |
| OA12505A (en) | 2006-05-29 |
| AP2003002894A0 (en) | 2003-12-31 |
| HUP0303725A2 (hu) | 2004-03-01 |
| MA26159A1 (fr) | 2004-07-01 |
| KR20030087069A (ko) | 2003-11-12 |
| IL158272A0 (en) | 2004-05-12 |
| EA200301109A1 (ru) | 2004-02-26 |
| HUP0303725A3 (en) | 2009-08-28 |
| MXPA03009344A (es) | 2004-02-12 |
| ATE417612T1 (de) | 2009-01-15 |
| JP2004525959A (ja) | 2004-08-26 |
| AU2002305164B2 (en) | 2005-07-28 |
| CA2443734A1 (en) | 2002-10-24 |
| EA006202B1 (ru) | 2005-10-27 |
| ES2319877T3 (es) | 2009-05-14 |
| NO20034513D0 (no) | 2003-10-08 |
| EP1385504B1 (en) | 2008-12-17 |
| ECSP034799A (es) | 2004-01-28 |
| CN1509170A (zh) | 2004-06-30 |
| BG108217A (bg) | 2004-12-30 |
| CZ20032767A3 (cs) | 2004-12-15 |
| ZA200307621B (en) | 2004-04-21 |
| NO20034513L (no) | 2003-12-04 |
| EP1385504A1 (en) | 2004-02-04 |
| EP1385504A4 (en) | 2007-03-14 |
| PL364526A1 (en) | 2004-12-13 |
| DE60230404D1 (pt) | 2009-01-29 |
| NZ528577A (en) | 2005-01-28 |
| WO2002083125A1 (en) | 2002-10-24 |
| CN1248692C (zh) | 2006-04-05 |
| BR0208789A (pt) | 2004-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026146T2 (de) | Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion | |
| ES2261523T3 (es) | Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria. | |
| JP2003501151A (ja) | 動脈再狭窄治療用装置および化合物 | |
| JP2003526594A (ja) | カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法 | |
| KR20010021865A (ko) | 카파 작용제 항소양성 약학적 조성물 및 이를 이용한소양증의 치료 방법 | |
| TWI251491B (en) | Pharmaceutical combinations | |
| JP2002527392A (ja) | 末梢的に作用する抗掻痒アヘン剤 | |
| KR20150120479A (ko) | 니트라이트의 약제학적 제형 및 이의 용도 | |
| KR20010021854A (ko) | 말초 작용성 항소양성 아편제 | |
| WO1997035579A1 (en) | A method for inhibiting clot formation | |
| UA59397C2 (uk) | Специфічний антагоніст рецептора 5нт2 для лікування розладу дихання уві сні | |
| JP3070930B2 (ja) | 脳血管性疾患治療剤および抗炎症剤 | |
| UA75395C2 (en) | Method for inhibiting adhesion formation | |
| KR100195651B1 (ko) | 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질 | |
| Cooper et al. | Reduction of post-surgical adhesion formation with tranilast | |
| JP2016175931A (ja) | 癒着の治療及び予防の方法 | |
| US5978698A (en) | Angioplasty procedure using nonionic contrast media | |
| DE69919789T2 (de) | Loratadin zur Verwendung als Antiarrhythmikum | |
| AU2002305164A1 (en) | Method of inhibiting adhesion formation | |
| DE60020951T2 (de) | Immunomodulierende zusammensetzungen enthaltend harnstoff derivate zur behandlung von entzündungskrankheiten | |
| US20040142918A1 (en) | Method of inhibiting adhesion formation | |
| KR101063605B1 (ko) | 정신분열증 치료제 | |
| JP2006510613A (ja) | ３，７−ジアザビシクロ［３．３．１］ノナン化合物を含有する液体医薬組成物および抗不整脈事象に関する治療法 | |
| DE3789173T2 (de) | Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall. | |
| TW391964B (en) | Pharmaceutical compositions for inhibiting vascular smooth muscle cell migration |